> ## Content Index
> Fetch the complete content index at: https://www.sharespective.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CSL is moving its American plasma centres back to Haemonetics, and the shares jumped 17.46%
- URL: https://www.sharespective.com/stories/csl-moving-american-plasma-centres-back-2026-10-09/
- Published: 2026-10-08T21:15:00.000Z
- Updated: 2026-10-19T19:29:13.000Z
- Description: Haemonetics rose 17.46% to US$119.47 on Thursday. CSL Plasma, the collection arm of Melbourne's CSL, now plans to move all its current US centres onto Haemonetics' NexSys collection machines by the end of 2027.
- Author: Shaun Botha
- Tags: Health care, #story, #group-health, CSL, Haemonetics

Haemonetics rose 17.46% to US$119.47 on Thursday. CSL Plasma, the collection arm of Melbourne's CSL, now plans to move all its current US centres onto Haemonetics' NexSys collection machines by the end of 2027.

**Why does a plasma machine matter so much?** CSL collects plasma from donors and turns it into medicines. Each donation needs a machine and a single-use kit, and Haemonetics sells both. CSL runs more than 300 centres in America, so the kits mean repeat sales for years.

This is a reunion. In 2021 CSL told Haemonetics it would not renew their supply contract, which brought in US$88.6 million that year, or 10.2% of revenue. CSL moved its centres to Terumo's Rika machines and finished the switch in mid-2025.

![Chart: Haemonetics' value sank, then CSL came back. Revenue for FY2022 to FY2026, US$m, left scale; market value at each year end, US$bn, right scale. The last point is the close before Thursday's 17.46% rise.](https://storage.ghost.io/c/02/71/0271df32-cec6-421f-9f13-b06ab90e54c1/content/images/2026/10/csl-moving-american-plasma-centres-back-2026-10-09-chart.jpg)

This story’s chart of the day.

The two signed a new agreement in August, covering only some centres, with the timing left open. Thursday's update covers all of them. The deal is still non-exclusive, and Haemonetics says the scope and timing can change.

What to watch 

the November results call, where Haemonetics has promised to put a number on the deal. Until then the 17% rise is the market's estimate. Our read is that the non-exclusive clause matters, because CSL has switched suppliers once already.

[ This story ran in Counting the Revenue Friday 9 October’s edition, with the market snapshot, the other two stories, the numbers and the week ahead. Read the whole edition → ](https://www.sharespective.com/sharespective-2026-10-09/)